Direct-acting antiviral agents for HCV infection affecting people who inject drugs
- 23 August 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Gastroenterology & Hepatology
- Vol. 14 (11), 641-651
- https://doi.org/10.1038/nrgastro.2017.106
Abstract
Globally, 12 million people are estimated to have injected drugs in the past year, 50% of whom have chronic HCV infection, with people who have previously injected drugs presenting an additional large reservoir of infection. The availability of simple and tolerable interferon-free direct-acting antiviral agents (DAAs) for HCV infection, which have a cure rate of >95% represents one of the most exciting advances in clinical medicine in the past few decades. Adherence and response to DAA therapy among people who inject drugs (PWID) receiving opioid substitution therapy (OST) in clinical trials are comparable to populations without a history of injecting drugs. Further data are required among current PWID not receiving OST. Given the potential prevention benefits of treatment, DAAs have enhanced cost-effectiveness among PWID. As HCV therapy is expanded to populations of PWID with high-risk behaviours for re-exposure, acknowledgement that HCV reinfection will occur is crucial, and appropriate strategies must be in place to maximize prevention of reinfection and offer retreatment for reinfection. This Review will also discuss essential components for broadening access to HCV care for PWID as we strive for the global elimination of HCV infection.Keywords
This publication has 125 references indexed in Scilit:
- A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance TreatmentAmerican Journal of Public Health, 2013
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Effectiveness of a Risk Screener in Identifying Hepatitis C Virus in a Primary Care SettingAmerican Journal of Public Health, 2012
- Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at riskDigestive and Liver Disease, 2012
- A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C TreatmentThe American Journal of Gastroenterology, 2011
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject DrugsThe Journal of Infectious Diseases, 2011
- General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community settingAustralian Journal of Primary Health, 2011
- Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and PlaceAmerican Journal of Epidemiology, 2008
- Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug usersEuropean Journal of Epidemiology, 2007